Empagliflozin is a drug classified as a SGLT2i, which is a protein located in the renal tubules responsible for reabsorbing glucose back into the bloodstream during the process of urine reabsorption.[34] Empagliflozin works by inhibiting SGLT2, reducing the reabsorption of glucose by renal tubules, thereby increasing the excretion of glucose in the urine and is primarily utilized for diabetes treatment.[35] In recent years, it has also been studied and utilized in the treatment of HF. The gene discussed is SLC5A2; the disease is diabetes mellitus.